Annual EBITDA
$1.03 B
+$45.97 M+4.66%
30 December 2023
Summary:
Charles River Laboratories International annual earnings before interest, taxes, depreciation & amortization is currently $1.03 billion, with the most recent change of +$45.97 million (+4.66%) on 30 December 2023. During the last 3 years, it has risen by +$263.65 million (+34.31%). CRL annual EBITDA is now at all-time high.CRL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$209.72 M
-$28.78 M-12.07%
28 September 2024
Summary:
Charles River Laboratories International quarterly earnings before interest, taxes, depreciation & amortization is currently $209.72 million, with the most recent change of -$28.78 million (-12.07%) on 28 September 2024. Over the past year, it has dropped by -$15.76 million (-6.99%). CRL quarterly EBITDA is now -41.29% below its all-time high of $357.25 million, reached on 31 December 2022.CRL Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$990.36 M
-$15.76 M-1.57%
28 September 2024
Summary:
Charles River Laboratories International TTM earnings before interest, taxes, depreciation & amortization is currently $990.36 million, with the most recent change of -$15.76 million (-1.57%) on 28 September 2024. Over the past year, it has dropped by -$76.24 million (-7.15%). CRL TTM EBITDA is now -7.15% below its all-time high of $1.07 billion, reached on 30 September 2023.CRL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRL EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +4.7% | -7.0% | -7.2% |
| 3 y3 years | +34.3% | +0.6% | +17.3% |
| 5 y5 years | +103.5% | +60.5% | +92.4% |
CRL EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +34.3% | -41.3% | +7.2% | -7.2% | +20.8% |
| 5 y | 5 years | at high | +103.5% | -41.3% | +64.1% | -7.2% | +92.4% |
| alltime | all time | at high | +390.1% | -41.3% | +133.3% | -7.2% | +335.1% |
Charles River Laboratories International EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $209.72 M(-12.1%) | $990.36 M(-1.6%) |
| June 2024 | - | $238.50 M(+8.7%) | $1.01 B(-0.3%) |
| Mar 2024 | - | $219.37 M(-32.0%) | $1.01 B(-2.2%) |
| Dec 2023 | $1.03 B(+4.7%) | $322.76 M(+43.1%) | $1.03 B(-3.2%) |
| Sept 2023 | - | $225.49 M(-6.6%) | $1.07 B(+1.6%) |
| June 2023 | - | $241.38 M(-0.5%) | $1.05 B(+1.7%) |
| Mar 2023 | - | $242.49 M(-32.1%) | $1.03 B(+4.8%) |
| Dec 2022 | $986.15 M(+20.2%) | $357.25 M(+70.9%) | $986.15 M(+13.2%) |
| Sept 2022 | - | $209.09 M(-6.8%) | $871.33 M(+0.1%) |
| June 2022 | - | $224.24 M(+14.7%) | $870.66 M(+1.5%) |
| Mar 2022 | - | $195.58 M(-19.3%) | $858.21 M(+4.6%) |
| Dec 2021 | $820.16 M(+6.7%) | $242.43 M(+16.3%) | $820.16 M(-2.8%) |
| Sept 2021 | - | $208.41 M(-1.6%) | $844.18 M(-0.6%) |
| June 2021 | - | $211.79 M(+34.4%) | $849.49 M(+6.4%) |
| Mar 2021 | - | $157.53 M(-40.9%) | $798.21 M(+3.9%) |
| Dec 2020 | $768.47 M(+36.5%) | $266.45 M(+24.7%) | $768.47 M(+12.4%) |
| Sept 2020 | - | $213.72 M(+33.2%) | $683.78 M(+13.8%) |
| June 2020 | - | $160.51 M(+25.6%) | $600.75 M(+5.5%) |
| Mar 2020 | - | $127.79 M(-29.7%) | $569.21 M(+1.1%) |
| Dec 2019 | $563.06 M(+11.0%) | $181.76 M(+39.1%) | $563.06 M(+9.4%) |
| Sept 2019 | - | $130.69 M(+1.3%) | $514.67 M(-0.7%) |
| June 2019 | - | $128.97 M(+6.0%) | $518.07 M(-0.6%) |
| Mar 2019 | - | $121.64 M(-8.8%) | $521.43 M(+2.8%) |
| Dec 2018 | $507.23 M(+10.8%) | $133.37 M(-0.5%) | $507.23 M(+4.8%) |
| Sept 2018 | - | $134.09 M(+1.3%) | $484.12 M(+4.3%) |
| June 2018 | - | $132.33 M(+23.2%) | $464.10 M(+3.6%) |
| Mar 2018 | - | $107.44 M(-2.6%) | $447.89 M(-2.2%) |
| Dec 2017 | $457.89 M(+21.4%) | $110.26 M(-3.3%) | $457.89 M(+0.8%) |
| Sept 2017 | - | $114.07 M(-1.8%) | $454.41 M(+4.5%) |
| June 2017 | - | $116.12 M(-1.1%) | $434.78 M(+4.9%) |
| Mar 2017 | - | $117.44 M(+10.0%) | $414.31 M(+9.8%) |
| Dec 2016 | $377.29 M(+23.5%) | $106.78 M(+13.1%) | $377.29 M(+7.8%) |
| Sept 2016 | - | $94.44 M(-1.3%) | $349.88 M(+4.1%) |
| June 2016 | - | $95.65 M(+18.9%) | $336.25 M(+2.4%) |
| Mar 2016 | - | $80.42 M(+1.3%) | $328.45 M(+7.6%) |
| Dec 2015 | $305.38 M(+6.8%) | $79.36 M(-1.8%) | $305.38 M(+3.5%) |
| Sept 2015 | - | $80.82 M(-8.0%) | $294.99 M(+2.7%) |
| June 2015 | - | $87.85 M(+53.2%) | $287.13 M(+3.5%) |
| Mar 2015 | - | $57.34 M(-16.9%) | $277.50 M(-3.0%) |
| Dec 2014 | $285.99 M(+11.7%) | $68.97 M(-5.5%) | $285.99 M(+5.0%) |
| Sept 2014 | - | $72.96 M(-6.7%) | $272.25 M(+0.4%) |
| June 2014 | - | $78.22 M(+18.8%) | $271.25 M(+5.2%) |
| Mar 2014 | - | $65.84 M(+19.2%) | $257.83 M(+0.7%) |
| Dec 2013 | $255.93 M(+4.7%) | $55.23 M(-23.2%) | $255.93 M(+0.0%) |
| Sept 2013 | - | $71.96 M(+11.0%) | $255.87 M(+6.0%) |
| June 2013 | - | $64.80 M(+1.3%) | $241.38 M(-1.4%) |
| Mar 2013 | - | $63.94 M(+15.9%) | $244.72 M(+0.1%) |
| Dec 2012 | $244.36 M | $55.17 M(-4.0%) | $244.36 M(-3.3%) |
| Sept 2012 | - | $57.46 M(-15.7%) | $252.79 M(-0.1%) |
| June 2012 | - | $68.14 M(+7.2%) | $252.98 M(-2.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | $63.58 M(-0.0%) | $260.12 M(-0.1%) |
| Dec 2011 | $260.48 M(-227.0%) | $63.60 M(+10.3%) | $260.48 M(-282.3%) |
| Sept 2011 | - | $57.65 M(-23.4%) | -$142.92 M(-16.9%) |
| June 2011 | - | $75.28 M(+17.7%) | -$172.03 M(-11.7%) |
| Mar 2011 | - | $63.94 M(-118.8%) | -$194.87 M(-5.0%) |
| Dec 2010 | -$205.15 M(-177.9%) | -$339.80 M(-1290.3%) | -$205.15 M(-208.4%) |
| Sept 2010 | - | $28.55 M(-45.6%) | $189.23 M(-18.3%) |
| June 2010 | - | $52.43 M(-2.3%) | $231.53 M(-9.1%) |
| Mar 2010 | - | $53.66 M(-1.7%) | $254.63 M(-3.3%) |
| Dec 2009 | $263.20 M(-174.0%) | $54.59 M(-23.0%) | $263.20 M(-162.5%) |
| Sept 2009 | - | $70.85 M(-6.2%) | -$421.17 M(+5.3%) |
| June 2009 | - | $75.54 M(+21.4%) | -$399.97 M(+4.9%) |
| Mar 2009 | - | $62.23 M(-109.9%) | -$381.37 M(+7.2%) |
| Dec 2008 | -$355.82 M(-210.6%) | -$629.78 M(-784.2%) | -$355.82 M(-200.0%) |
| Sept 2008 | - | $92.05 M(-2.2%) | $355.65 M(+1.7%) |
| June 2008 | - | $94.13 M(+7.2%) | $349.82 M(+4.6%) |
| Mar 2008 | - | $87.78 M(+7.5%) | $334.27 M(+3.9%) |
| Dec 2007 | $321.81 M(+17.7%) | $81.68 M(-5.3%) | $321.81 M(+4.5%) |
| Sept 2007 | - | $86.22 M(+9.7%) | $307.81 M(+4.3%) |
| June 2007 | - | $78.59 M(+4.4%) | $295.00 M(+3.4%) |
| Mar 2007 | - | $75.31 M(+11.3%) | $285.19 M(+96.8%) |
| Dec 2006 | $273.30 M(-0.5%) | $67.69 M(-7.8%) | $144.94 M(+11.8%) |
| Sept 2006 | - | $73.40 M(+6.7%) | $129.63 M(-6.3%) |
| June 2006 | - | $68.79 M(-205.9%) | $138.34 M(+0.5%) |
| Mar 2006 | - | -$64.93 M(-224.0%) | $137.62 M(-49.8%) |
| Dec 2005 | $274.81 M(+36.1%) | $52.38 M(-36.2%) | $274.02 M(+0.9%) |
| Sept 2005 | - | $82.11 M(+20.6%) | $271.66 M(+12.5%) |
| June 2005 | - | $68.06 M(-4.8%) | $241.40 M(+7.0%) |
| Mar 2005 | - | $71.47 M(+42.9%) | $225.69 M(+11.8%) |
| Dec 2004 | $201.92 M(+19.0%) | $50.02 M(-3.5%) | $201.92 M(+2.9%) |
| Sept 2004 | - | $51.86 M(-0.9%) | $196.18 M(+5.3%) |
| June 2004 | - | $52.34 M(+9.7%) | $186.23 M(+5.6%) |
| Mar 2004 | - | $47.70 M(+7.7%) | $176.34 M(+3.9%) |
| Dec 2003 | $169.67 M(+14.7%) | $44.28 M(+5.7%) | $169.67 M(+3.9%) |
| Sept 2003 | - | $41.91 M(-1.3%) | $163.25 M(+1.6%) |
| June 2003 | - | $42.46 M(+3.5%) | $160.70 M(+3.8%) |
| Mar 2003 | - | $41.03 M(+8.4%) | $154.80 M(+4.6%) |
| Dec 2002 | $147.99 M(+24.5%) | $37.86 M(-3.8%) | $147.99 M(+5.1%) |
| Sept 2002 | - | $39.36 M(+7.7%) | $140.80 M(+5.9%) |
| June 2002 | - | $36.56 M(+6.8%) | $132.94 M(+4.0%) |
| Mar 2002 | - | $34.22 M(+11.6%) | $127.81 M(+7.5%) |
| Dec 2001 | $118.86 M(+41.6%) | $30.67 M(-2.6%) | $118.86 M(+11.3%) |
| Sept 2001 | - | $31.49 M(+0.2%) | $106.78 M(+9.2%) |
| June 2001 | - | $31.44 M(+24.4%) | $97.81 M(+13.3%) |
| Mar 2001 | - | $25.27 M(+36.0%) | $86.36 M(+2.9%) |
| Dec 2000 | $83.93 M(+43.2%) | $18.58 M(-17.5%) | $83.93 M(+28.4%) |
| Sept 2000 | - | $22.53 M(+12.7%) | $65.35 M(+52.6%) |
| June 2000 | - | $19.98 M(-12.5%) | $42.82 M(+87.5%) |
| Mar 2000 | - | $22.84 M | $22.84 M |
| Dec 1999 | $58.61 M(+26.8%) | - | - |
| Dec 1998 | $46.22 M | - | - |
FAQ
- What is Charles River Laboratories International annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Charles River Laboratories International?
- What is Charles River Laboratories International annual EBITDA year-on-year change?
- What is Charles River Laboratories International quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Charles River Laboratories International?
- What is Charles River Laboratories International quarterly EBITDA year-on-year change?
- What is Charles River Laboratories International TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Charles River Laboratories International?
- What is Charles River Laboratories International TTM EBITDA year-on-year change?
What is Charles River Laboratories International annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of CRL is $1.03 B
What is the all time high annual EBITDA for Charles River Laboratories International?
Charles River Laboratories International all-time high annual earnings before interest, taxes, depreciation & amortization is $1.03 B
What is Charles River Laboratories International annual EBITDA year-on-year change?
Over the past year, CRL annual earnings before interest, taxes, depreciation & amortization has changed by +$45.97 M (+4.66%)
What is Charles River Laboratories International quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of CRL is $209.72 M
What is the all time high quarterly EBITDA for Charles River Laboratories International?
Charles River Laboratories International all-time high quarterly earnings before interest, taxes, depreciation & amortization is $357.25 M
What is Charles River Laboratories International quarterly EBITDA year-on-year change?
Over the past year, CRL quarterly earnings before interest, taxes, depreciation & amortization has changed by -$15.76 M (-6.99%)
What is Charles River Laboratories International TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of CRL is $990.36 M
What is the all time high TTM EBITDA for Charles River Laboratories International?
Charles River Laboratories International all-time high TTM earnings before interest, taxes, depreciation & amortization is $1.07 B
What is Charles River Laboratories International TTM EBITDA year-on-year change?
Over the past year, CRL TTM earnings before interest, taxes, depreciation & amortization has changed by -$76.24 M (-7.15%)